当前位置： SCI文献检索 > Experimental and Therapeutic Medicine期刊下所有文献 > Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy.

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy.

Abstract：

:There are limited data available on the regression of fibrosis in hepatitis C virus (HCV) patients who have achieved sustained virologic response (SVR) after interferon-free treatments. Moreover, a perfect method for assessing liver fibrosis and its dynamics has not been established yet. The main objective of this study was to evaluate the dynamics of aspartate aminotransferase to platelet ratio index (APRI) and Fibrosis-4 (FIB-4) scores in patients with HCV who registered SVR. We performed ROC curve analysis to evaluate the diagnostic performance of APRI and FIB-4 scores in determining the presence of cirrhosis in comparison to FibroTest. In total 251 patients were enrolled: 164 cirrhotic and 83 non-cirrhotic patients, and they were evaluated at baseline, at 6 and at 12 months post-end of treatment (EOT). In the cirrhotic group, at baseline, there was a weak but statistically significant correlation between APRI and FibroTest (τ=0.173, P=0.001), as well as between FIB-4 and FibroTest (τ=0.265, P<0.001). At the 6-month follow-up, APRI no longer correlated with FibroTest (τ=0.144, P=0.057), while FIB-4 was correlated (τ=0.256, P=0.001). The same pattern was shown at 12 months post-EOT. Between baseline and the 6-month evaluation, there was a significant decrease in APRI (P<0.001) and FIB-4 (P<0.001) scores, but for the next follow-up period, there was no reduction. In the non-cirrhotic group, APRI and FIB-4 did not correlate with the FibroTest value at any of the evaluation times. There was a significant difference between baseline and the 6-month visit for APRI (P=0.01) and for FIB-4 (P=0.014). The areas under the receiver operating characteristics curve (AUROCs) for the presence of cirrhosis compared with FibroTest for APRI and FIB-4 were 0.682 [95% confidence interval (CI), 0.613-0.752] and 0.693 (95% CI 0.625-0.76). Both APRI and FIB-4 prove to be easy, quick and inexpensive tools for screening HCV cirrhosis, with moderate diagnostic accuracy and FIB-4 can be useful for monitoring patients post-EOT.

journal_name

Exp Ther Med

journal_title

Experimental and therapeutic medicine

authors

Leuştean A,Popescu C,Nichita L,Tilişcan C,Aramă V

doi

10.3892/etm.2020.9531

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

issue

eissn

1792-0981

issn

1792-1015

pii

ETM-0-0-09531

journal_volume

pub_type

杂志文章

在线工具

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy.